Consumer Healthcare

An exclusive dual action against gas and bloating that favors a fast gas elimination and restores a healthy gut microbiota.

This liquid formulation is used in the short-term treatment of acute diarrhea, in addition to use for dietary and rehydration measures, coming in a ready to use liquid stick.

forlax® is an oral osmotic laxative, designed and developed by Ipsen, and indicated for the treatment of constipation in both adults and children. The active substance in forlax® is Macrogol 4000, a linear polymer of polyethylene glycol (PEG) of high molecular weight.

As of 31 December 2017, forlax® was granted marketing authorizations in about 50 countries. In 2017, 49% of forlax® sales were generated in France.

fortrans® is aimed at intestinal cleansing before endoscopy procedure (colonoscopy), surgery, or radiology. The active substance in fortrans® is Macrogol 4000, a linear polymer of polyethylene glycol (PEG) of high molecular weight with added electrolytes.

fortrans® is available in more than 40 countries. Russia and Poland are the two largest markets, which represent 40% of fortrans® sales.

eziclen® is a next-generation osmotic laxative, indicated in adults, for cleaning the bowel before endoscopy procedure (coloscopy), surgery or radiology.

In 2009, Ipsen acquired from Braintree the exclusive manufacturing, marketing and distribution rights of the proprietary formulation BLI-800 for the European Union, the Commonwealth of Independent States (CIS), some Asian countries (including China) and some North African and South American countries. On 31 December 2017, eziclen® was marketed by Ipsen or its local partners in 20 countries.

Etiasa® (mesalazine) is indicated in Inflammatory Bowel Diseases (Ulcerative colitis and Crohn’s Disease), for the treatment of mildl to moderate conditions and maintenance of remission.

In 2015, Ipsen renewed its exclusive agreement with Ethypharm to promote and distribute etiasa® in China.

An antispasmodic; sold in the Czech Republic, Estonia, Hungary, Latvia, Poland and Slovakia

Un laxatif, commercialisé en République Tchèque.

Adenuric® (febuxostat) 80 mg and 120 mg (tablets) is indicated for the treatment of chronic hyperuricaemia with clinical manifestations of urate deposition (including a history or presence of tophus and/or gouty arthritis). In 2015, some indications were added for Adenuric® 120 mg for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

The Group granted exclusive licensing rights to the Menarini Group for Adenuric® in 41 countries. In addition, Ipsen continues to promote the product in France together with Menarini.

tanakan® contains natural substances with antioxidant and neuro-protective properties.

tanakan® is indicated for the treatment of cognitive disorders (memory or attention deficit) in the elderly. The active substance in tanakan® – EGb 761® – is a standardized extract from the leaves of Ginkgo biloba (dioecious tree in the Ginkgoaceae family) cultivated and extracted under controlled conditions.

As of 31 December 2017, tanakan® was approved in approximately 50 countries, mainly in Europe, Russia, and Asia. In 2017, 20% of tanakan® sales were generated in Russia, where the product is offered as a self-medication OTC product.

An analgesic for the treatment of moderate to severe pain.

Used for irritative cough, allergic cough, non productive cough with heart disease, tracheitis, bronchitis and other conditions.

forlaxGo® is a laxative treatment for the symptomatic treatment of occasional constipation in adults and children from 8 years of age coming in a ready to use liquid stick

smebiocta^® (LP299V^®), the first probiotic launched by Ipsen to maintain intestinal comfort.

In April 2016, Ipsen signed a license and supply agreement with Probi for the commercialization of its probiotic strain Lactobacillus Plantarum 299v (LP299V®). The agreement covers 18 markets, many with high growth potential, with an option to include additional countries.

In 2017, the product was launched in France, Czech Republic, Romania, and the Baltics.